In vivo efficacy of antimicrobials against biofilm-producing Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4974-4981

  Pawar, Vinay ^a   Komor, Uliana ^a   Kasnitz, Nadine ^a   Bielecki, Piotr ^c   Pils, Marina C ^a   Gocht, Benjamin ^b   Moter, Annette ^b   Rohde, Manfred ^a   Weiss, Siegfried ^a   Häussler, Susanne ^c  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COLISTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIUM MUTANT; BIOFILM; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; ELECTRON MICROSCOPY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SOLID TUMOR; TRANSPOSON; TUMOR MODEL; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; LUNG DISEASES; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; PSEUDOMONAS INFECTIONS; TUMOR CELL LINE;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOFILMS; CELL LINE, TUMOR; COLISTIN; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; FEMALE; LUNG DISEASES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 84939865006     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00194-15     Document Type: Article

References (38)

1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596. http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9.
2. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. 2003. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36:1418-1423. http://dx.doi.org/10.1086/375057.
3. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43:1379-1382.
4. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. http://dx.doi.org/10.1016/S0140-6736(01)05321-1.
5. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. 2003. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 112:1466-1477. http://dx.doi.org/10.1172/JCI20365.
6. Hall-Stoodley L, Stoodley P. 2009. Evolving concepts in biofilm infections. Cell Microbiol 11:1034-1043. http://dx.doi.org/10.1111/j.1462-5822.2009.01323.x.
7. Fux CA, Costerton JW, Stewart PS, Stoodley P. 2005. Survival strategies of infectious biofilms. Trends Microbiol 13:34-40. http://dx.doi.org/10.1016/j.tim.2004.11.010.
8. Wilkins M, Hall-Stoodley L, Allan RN, Faust SN. 2014. New approaches to the treatment of biofilm-related infections. J Infect 69(Suppl 1):S47-S52. http://dx.doi.org/10.1016/j.jinf.2014.07.014.
9. Bjarnsholt T, Ciofu O, Molin S, Givskov M, Høiby N. 2013. Applying insights from biofilm biology to drug development - can a new approach be developed? Nat Rev Drug Discov 12:791-808. http://dx.doi.org/10.1038/nrd4000.
10. Davies D. 2003. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2:114-122. http://dx.doi.org/10.1038/nrd1008.
11. Mah TC, O'Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34-39. http://dx.doi.org/10.1016/S0966-842X(00)01913-2.
12. Brooun A, Liu S, Lewis K, Lewis KIM. 2000. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 44:640-646. http://dx.doi.org/10.1128/AAC.44.3.640-646.2000.
13. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. 2008. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 68:223-240. http://dx.doi.org/10.1111/j.1365-2958.2008.06152.x.
14. Bragonzi A. 2010. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 300:584-593. http://dx.doi.org/10.1016/j.ijmm.2010.08.012.
15. Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Fessler MB, Malcolm KC, Vasil ML, Nick JA. 2005. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 73:3693-3701. http://dx.doi.org/10.1128/IAI.73.6.3693-3701.2005.
16. Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA, Lory S, Brodie EL, Lynch SV, Bohannan BJM, Green JL, Maurer BA, Kolter R. 2010. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 12:1293-1303. http://dx.doi.org/10.1111/j.1462-2920.2010.02173.x.
17. van Heeckeren AM, Schluchter MD. 2002. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 36:291-312. http://dx.doi.org/10.1258/002367702320162405.
18. Pawar V, Crull K, Komor U, Kasnitz N, Frahm M, Kocijancic D, Westphal K, Leschner S, Wolf K, Loessner H, Rohde M, Häussler S, Weiss S. 2014. Murine solid tumours as a novel model to study bacterial biofilm formation in vivo. J Intern Med 276:130-139. http://dx.doi.org/10.1111/joim.12258.
19. Crull K, Rohde M, Westphal K, Loessner H, Wolf K, Felipe-López A, Hensel M, Weiss S. 2011. Biofilm formation by Salmonella enterica serovar Typhimurium colonizing solid tumours. Cell Microbiol 13:1223-1233. http://dx.doi.org/10.1111/j.1462-5822.2011.01612.x.
20. Komor U, Bielecki P, Loessner H, Rohde M, Wolf K, Westphal K, Weiss S, Häussler S. 2012. Biofilm formation by Pseudomonas aeruginosa in solid murine tumors - a novel model system. Microbes Infect 14:951-958. http://dx.doi.org/10.1016/j.micinf.2012.04.002.
21. Bielecki P, Komor U, Bielecka A, Müsken M, Puchałka J, Pletz MW, Ballmann M, Martins dos Santos VA, Weiss S, Häussler S. 2013. Ex vivo transcriptional profiling reveals a common set of genes important for the adaptation of Pseudomonas aeruginosa to chronically infected host sites. Environ Microbiol 15:570-587. http://dx.doi.org/10.1111/1462-2920.12024.
22. Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G. 2010. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 202:1585-1592. http://dx.doi.org/10.1086/656788.
23. Diggle SP, Winzer K, Chhabra SR, Worrall KE, Cámara M, Williams P. 2003. The Pseudomonas aeruginosa quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol Microbiol 50:29-43. http://dx.doi.org/10.1046/j.1365-2958.2003.03672.x.
24. Müsken M, Di Fiore S, Dötsch A, Fischer R, Häussler S. 2010. Genetic determinants of Pseudomonas aeruginosa biofilm establishment. Microbiology 156:431-441. http://dx.doi.org/10.1099/mic.0.033290-0.
25. Friedman L, Kolter R. 2004. Genes involved in matrix formation in Pseudomonas aeruginosa PA14 biofilms. Mol Microbiol 51:675-690.
26. Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, Wu G, Villanueva J, Wei T, Ausubel FM. 2006. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants Proc Natl Acad Sci USA 103:2833-2838. http://dx.doi.org/10.1073/pnas.0511100103.
27. Mallmann C, Siemoneit S, Schmiedel D, Petrich A, Gescher DM, Halle E, Musci M, Hetzer R, Göbel UB, Moter A. 2010. Fluorescence in situ hybridization to improve the diagnosis of endocarditis: a pilot study. Clin Microbiol Infect 16:767-773. http://dx.doi.org/10.1111/j.1469-0691.2009.02936.x.
28. Moter A, Leist G, Rudolph R, Schrank K, Choi B-K, Wagner M, Göbel UB. 1998. Fluorescence in situ hybridization shows spatial distribution of as yet uncultured treponemes in biopsies from digital dermatitis lesions. Microbiology 144:2459-2467. http://dx.doi.org/10.1099/00221287-144-9-2459.
29. Braun-Howland EB, Vescio PA, Nierzwicki-Bauer SA. 1993. Use of a simplified cell blot technique and 16S rRNA-directed probes for identification of common environmental isolates. Appl Environ Microbiol 59:3219-3224.
30. Römling U, Rohde M, Olsén A, Normark S, Reinköster J. 2000. AgfD the checkpoint of multicellular and aggregative behaviour in Salmonella typhimurium regulates at least two independent pathways. Mol Microbiol 36:10-23. http://dx.doi.org/10.1046/j.1365-2958.2000.01822.x.
31. Crull K, Bumann D, Weiss S. 2011. Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol 62:75-83. http://dx.doi.org/10.1111/j.1574-695X.2011.00790.x.
32. Döring G, Hoiby N. 2004. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 3:67-91.
33. Leschner S, Westphal K, Dietrich N, Viegas N, Jablonska J, Lyszkiewicz M, Lienenklaus S, Falk W, Gekara N, Loessner H, Weiss S. 2009. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-α. PLoS One 4:e6692. http://dx.doi.org/10.1371/journal.pone.0006692.
34. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222. http://dx.doi.org/10.1128/CMR.15.2.194-222.2002.
35. Rajan S, Saiman L. 2002. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 17:47-56. http://dx.doi.org/10.1053/srin.2002.31690.
36. Christensen LD, van Gennip M, Jakobsen TH, Alhede M, Hougen HP, Høiby N, Bjarnsholt T, Givskov M. 2012. Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorumsensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J Antimicrob Chemother 67:1198-1206. http://dx.doi.org/10.1093/jac/dks002.
37. Høiby N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 9:32. http://dx.doi.org/10.1186/1741-7015-9-32.
38. Pustelny C, Komor U, Pawar V, Lorenz A, Bielecka A, Moter A, Gocht B, Eckweiler D, Müsken M, Grothe C, Lünsdorf H, Weiss S, Häussler S. 2015. Contribution of Veillonella parvula to Pseudomonas aeruginosa-mediated pathogenicity in a murine tumor model system. Infect Immun 83:417-429. http://dx.doi.org/10.1128/IAI.02234-14.